Bristol Myers Squibb (CELG-RI) Short term Debt (2009 - 2026)

Bristol Myers Squibb has disclosed Short term Debt across 18 years of filings, most recently posting $2.3 billion for Q1 2026.

• In Q1 2026, Short term Debt fell 35.06% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 35.06% YoY), while the FY2025 annual figure was $2.3 billion, up 10.51% from the prior year.
• Short term Debt improved to $2.3 billion in Q1 2026, from $2.3 billion in the prior quarter.
• Over the last five years, Short term Debt for CELG-RI reached as high as $7.5 billion in Q1 2022 and fell as low as $1.1 billion in Q3 2024.
• The 5-year median for Short term Debt is $3.5 billion (2024), against an average of $3.7 billion.
• Annual changes were most pronounced in 2022 — Short term Debt surged 323.3% — and 2024, when it tumbled 80.28%.
• A 5-year view of Short term Debt shows it stood at $4.3 billion in 2022, then declined by 26.85% to $3.1 billion in 2023, then tumbled by 34.4% to $2.0 billion in 2024, then gained by 10.51% to $2.3 billion in 2025, then climbed by 2.08% to $2.3 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $2.3 billion, $2.3 billion, and $4.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.